Company intelligence / Profile preview

Avanzanite Bioscience

Ownership: Private
Development stage: Other

Overview

Avanzanite has two authorized medicinal products in its portfolio. In 2024, they reached over 120 patients across 12 markets and generated revenue in six countries. The European Commission granted marketing authorization for AKANTIOR® (polihexanide) for the treatment of acanthamoeba keratitis in August 2024. They also distribute Sibnayal® for a rare pediatric kidney disease.

Therapeutic areas: OphthalmologyRare DiseasesNephrologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Partnerships

SIFI (for AKANTIOR®)Advicenne (for Sibnayal®)

Beyond the preview

Go deeper on Avanzanite Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avanzanite Bioscience.